Page last updated: 2024-08-16

ribavirin and telaprevir

ribavirin has been researched along with telaprevir in 455 studies

Research

Studies (455)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (3.96)	29.6817
2010's	431 (94.73)	24.3611
2020's	6 (1.32)	2.80

Authors

Authors	Studies
Bartels, DJ; Brennan, DL; Hanzelka, BL; Kwong, AD; Lin, C; Müh, U; Rao, BG; Swenson, L; Tigges, AM; Wei, Y; Zhou, Y	1
Bartels, DJ; Brennan, DL; Chu, HM; Hanzelka, BL; Kwong, AD; Lin, C; Müh, U; Rao, BG; Swenson, L; Tigges, AM; Wei, Y; Zhou, Y	1
Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Gao, RM; Li, SY; Li, YH; Li, ZR; Peng, ZG; Shan, GZ; Wu, LT; Zhang, DJ; Zhong, ZJ; Zuo, LM	1
Cen, S; Chen, J; Jiang, X; Jiang, Z; Jin, J; Li, J; Li, Y; Li, Z; Peng, Z; Quan, Y; Tan, J; Wang, Y	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Jacobson, I; Sigal, S	1
Iino, S	1
Khunvichai, A; Kieffer, TL; Lawitz, E; McHutchison, JG; McNair, L; Muir, AJ; Rodriguez-Torres, M	1
Zeuzem, S	2
Pár, A; Pár, G	1
Kronenberger, B; Zeuzem, S	2
Alam, J; Everson, GT; Gordon, SC; Jacobson, IM; Kauffman, R; McHutchison, JG; McNair, L; Muir, AJ; Sulkowski, M	1
Alam, J; Bengtsson, L; Bourlière, M; Bronowicki, JP; Dusheiko, G; Ferenci, P; Forestier, N; George, S; Gharakhanian, S; Goeser, T; Hézode, C; Kauffman, RS; Kieffer, T; Kwong, A; McNair, L; Pawlotsky, JM; Pol, S; Zeuzem, S	1
Hoofnagle, JH	1
Kao, JH	1
Nelson, DR	2
Angelico, M; Baiocchi, L; Carbone, M; Lenci, I	1
Takehara, T	1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H	1
Adda, N; Afdhal, NH; Bsharat, M; Di Bisceglie, AM; Garg, J; George, S; Heathcote, EJ; Jacobson, IM; Kauffman, RS; Manns, MP; McHutchison, JG; Muir, AJ; Reesink, HW; Terrault, NA; Zeuzem, S	1
Shiffman, ML	1
Rustgi, VK	1
Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Nakamura, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H	2
Fowell, AJ; Nash, KL	1
Cardot-Leccia, N; Lacour, JP; Montaudié, H; Passeron, T; Sebbag, N	1
Beumont, M; Carosi, G; De Backer, K; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Luo, D; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L; Van Heeswijk, R	1
Poordad, F	1
Burney, T; Dusheiko, G	1
Fried, MW	1
Asselah, T; Marcellin, P	2
Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kamatani, N; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Nakamura, Y; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y	1
Pawlotsky, JM	1
Ciesek, S; Manns, MP	1
Akaike, J; Arakawa, T; Chayama, K; Kamiya, N; Karino, Y; Kumada, H; Kuwata, Y; Ohmura, T; Ozeki, I; Sato, T; Toyota, J; Yamada, I	1
Hunyady, B	1
Abe, H; Akuta, N; Chayama, K; Hayes, CN; Kamatani, N; Karino, Y; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Sezaki, H; Suzuki, F; Toyota, J	1
Schlütter, J	1
Andreone, P; Beumont, M; Boogaerts, G; De Meyer, S; Diago, M; Ferenci, P; Focaccia, R; Foster, GR; Horban, A; Lawitz, E; Luo, D; Müllhaupt, B; Nevens, F; Picchio, G; Pockros, P; Pol, S; Polo, R; Roberts, S; Shouval, D; Terg, R; Van Heeswijk, R; van Hoek, B; Weiland, O; Younossi, Z; Zeuzem, S	1
Beumont, M; Bronowicki, JP; Carosi, G; Foster, GR; Hézode, C; Picchio, G; van Baelen, B; van Heeswijk, R; Verlinden, L; Weiland, O	1
Cabrera, R; Draganov, PV; Limaye, AR	1
Corouge, M; Pol, S	2
Chung, TL; Herrmann, E; Hofmann, WP; Karey, U; Lötsch, J; Mihm, U; Osbahr, C; Sarrazin, C; Susser, S; Welsch, C; Zeuzem, S	1
Chayama, K; Hayashi, N; Kumada, H; Okanoue, T; Toyota, J; Tsubouchi, H	2
Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M	1
Ilyas, JA; Vierling, JM	1
Bourlière, M; Buggisch, P; Cacoub, P; Dupin, N; Dusheiko, G; Hézode, C; Lübbe, J; Picard, O; Pujol, R; Roujeau, JC; Segaert, S; Thio, B	1
Bruno, R; Fagiuoli, S; Sacchi, P	1
Adda, N; Adler, M; Afdhal, NH; Everson, GT; Flamm, SL; Fried, MW; George, S; Kauffman, RS; Martin, M; Nelson, DR; Poordad, F; Reesink, HW; Sankoh, AJ; Sherman, KE; Sulkowski, MS; Wright, CI	1
Razonable, RR	1
Stiefelhagen, P	1
Adda, N; Berg, T; Dusheiko, G; Ferenci, P; George, S; Heathcote, EJ; Kauffman, RS; Martin, EC; McHutchison, JG; Muir, AJ; Pawlotsky, JM; Poordad, FF; Reesink, HW; Shiffman, ML; Zeuzem, S	1
Hurter, P; Kauffman, RS; Kwong, AD; Mueller, P	1
Karino, Y; Ozeki, I; Toyota, J	1
Battyáni, Z; Hunyady, B; Kovács, B	1
Muir, AJ	1
Buti, M; Homs, M	1
Botfield, M; de Bruijne, J; Kieffer, TL; Molenkamp, R; Reesink, H; Schinkel, J; Shames, B; Sullivan, JC; Weegink, C	1
Nehra, V; Rizza, SA; Talwani, R; Temesgen, Z	1
Ferenci, P; Reddy, KR	1
Butt, AA; Kanwal, F	1
Jacobson, I; Liapakis, AM	1
Hézode, C	2
Kwo, PY	1
Forestier, N; Zeuzem, S	2
Bacon, BR; Khalid, O	1
Esteban, R; Shiffman, ML	1
Foster, GR; Serfaty, LD	1
Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C	1
Roche, B; Samuel, D	1
Sulkowski, MS	1
Mangia, A; Mottola, L	1
Kumar, CK; Sarin, SK	1
El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M	1
Fried, MW; McGowan, CE	1
Barreiro, P; Labarga, P; Poveda, E; Soriano, V; Vispo, E	1
Agarwal, K; Austin, A; Brown, A; Dillon, JF; Foster, GR; Fox, R; Fraser, A; Hayes, PC; Leen, C; Mills, PR; Mutimer, DJ; Ramachandran, P; Ryder, SD	1
Hézode, C; Pawlotsky, JM; Sarrazin, C; Zeuzem, S	1
Cheiab, B; Ioniţă-Radu, F; Raşcanu, A	1
Crespo, G; Lens, S	1
Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E	1
Beumont, M; Carosi, G; DeMasi, R; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Lonjon-Domanec, I; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L	1
Domínguez Muñoz, E; Fernández Castroagudín, J; Molina Pérez, E	1
Francque, S; Ho, E; Michielsen, P	1
Perry, CM	1
Dallmeier, K; Neyts, J; Paeshuyse, J	1
Casey, LC; Lee, WM	1
Saxena, V; Terrault, N	1
Amur, S; Birnkrant, D; Fleischer, R; Hammerstrom, T; Jadhav, PR; Lewis, L; Liu, J; Naeger, L; O'Rear, J; Pacanowski, M; Robertson, S; Seo, S; Soon, G	1
Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM	1
Adda, N; Adiwijaya, B; Bartels, DJ; Beumont, M; De Meyer, S; Dierynck, I; Dorrian, J; Ghys, A; Jacobson, IM; Jiang, M; Kauffman, RS; Kieffer, TL; Kwong, AD; Picchio, G; Sherman, KE; Spanks, J; Sullivan, JC; Tigges, A; Zeuzem, S; Zhang, EZ	1
Chang, MF; Lim, J; Monto, A; Morgan, TR; Pocha, C; Ross, D; Yee, HS	1
Chevaliez, S; Pawlotsky, JM; Rodriguez, C	1
Barritt, AS; Fried, MW	1
Naggie, S; Sulkowski, MS	1
Thompson, AJ	1
Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M	1
Enomoto, N; Sakamoto, M	1
Amur, S; Pacanowski, M; Zineh, I	1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y	1
Pearlman, BL	1
Dybowska, D; Halota, W; Kozielewicz, D	2
Fadda, V; Maratea, D; Messori, A; Trippoli, S	1
Bartels, DJ; Beumont, M; Daems, B; De Meyer, S; Dierynck, I; Ghys, A; Kieffer, TL; Picchio, G; Sullivan, JC; Van Baelen, B; Zeuzem, S	1
Burton, MJ; McGuire, BM; Passarella, MJ	1
Bourlière, M; Bronowicki, JP; Delasalle, P; Leroy, V; Pageaux, GP; Pariente, A; Pol, S; Serfaty, L; Zoulim, F	1
Houlihan, DD; Mutimer, DJ; Rowe, IA	1
Grammatikos, G; Vermehren, J; Zeuzem, S	1
Dusheiko, G; Wedemeyer, H	1
Berg, CP; Egetemeyr, DP; Königsrainer, A; Lauer, UM; Malek, NP; Nadalin, S; Werner, CR	1
Beaumont, M; Garg, V; Kauffman, RS; van Heeswijk, RP	1
Cachay, ER	1
Ouzan, D	1
Chandy, GM; Conjeevaram, H; Jothimani, D	1
Pascale, A; Serfaty, L	1
Flemming, JA; Terrault, NA	1
Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA	1
Dumortier, J; Gagnieu, MC; Guillaud, O; Janbon, B; Juillard, L; Leroy, V; Morelon, E	1
Asselah, T	2
Ikeda, F; Iwasaki, Y; Yamamoto, K	1
Adda, N; Bartels, DJ; Bengtsson, L; Gritz, L; Jacobson, IM; Kauffman, RS; Kieffer, TL; Luo, D; Picchio, G; Tomaka, F	1
Cooper, C; Druyts, E; El Khoury, AC; Lester, R; Mills, EJ; Thorlund, K; Yaya, S	1
Jacobson, IM; Jesudian, AB	2
Burton, JR; Everson, GT	1
Andreone, P; Beumont, M; De Meyer, S; Diago, M; Foster, GR; George, S; Lawitz, EJ; Lonjon-Domanec, I; Luo, D; Picchio, G; Pockros, PJ; Pol, S; Roberts, S; Younossi, Z; Zeuzem, S	1
Gane, E	1
Chayama, K; Hayes, CN; Kawakami, Y; Ohishi, W	1
Lemon, M	1
Buti, M; Esteban, R	1
Sarrazin, C; Vermehren, J	1
Izumi, N; Kurosaki, M; Suzuki, S; Tamaki, N	1
Guo, Z; He, X; Kong, Y; Liang, W; Ling, X; Schroder, PM; Shang, Y; Wang, X	1
Chazouillères, O; Pascale, A; Serfaty, L	1
Aerssens, J; Andreone, P; Beumont, M; Botfield, M; De Meyer, S; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Luo, D; Picchio, G; Pockros, PJ; Pol, S; Roberts, S; Van Heeswijk, RP; Younossi, Z; Zeuzem, S	1
Chen, Q; Chen, W; Gu, L; Liang, B; Su, L; Tan, J; Tang, N; Wu, G; Wu, P; Xie, J; Yan, Y	1
Comee, MK; Malloy, M; Silva, M; Sitole, M; Spooner, L	1
Cornberg, M; Kirschner, J; Maasoumy, B; Manns, MP; Markova, AA; Mix, C; Port, K; Rogalska-Taranta, M; Serrano, BC; Sollik, L; Wedemeyer, H	1
Heil, EL; Hynicka, LM	1
Davis, GL; Klintmalm, GB; McKenna, GJ; O'Leary, JG	1
Blum, R; Kessebohm, K; Pfaundler, N; Stickel, F; Stieger, M	1
Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D	1
Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC	1
Bota, S; Neghină, AM; Popescu, A; Şirli, R; Sporea, I; Străin, M	1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y	4
de Jong, YP; Jacobson, IM; Jesudian, AB	1
Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y	1
Aguilera, V; Berenguer, M; Vinaixa, C	1
Apica, B; Chen, EY; Czul, F; Dubin, P; Lee, WM; Martin, P; Sclair, SN	1
Bazin-Karra, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Longuet, M; Musset, L; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM	1
Aouri, M; Buclin, T; Cavassini, M; Csajka, C; Decosterd, LA; Mercier, T; Moradpour, D; Rauch, A; Telenti, A	1
Beumont, M; Ceulemans, H; De Meyer, S; Dierynck, I; Foster, GR; Ghys, A; Lin, TI; Picchio, G; Van Baelen, B	1
Schmutz, JL; Trechot, P	1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F	1
Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Okada, K; Shimizu, M; Takayama, K; Toyoda, K	1
Adda, N; Adiwijaya, B; Bsharat, M; Dieterich, DT; Garg, V; Gharakhanian, S; Girard, PM; Henshaw, J; Mahnke, L; McCallister, S; Rockstroh, JK; Rubin, RA; Sherman, KE; Soriano, V; Sulkowski, MS	1
Aqel, BA; Charlton, MR; Henry, TM; Keaveny, AP; Koning, L; Murphy, JL; Pungpapong, S; Rosser, BG; Ryland, KL; Satyanarayana, R; Vargas, HE; Yataco, ML	1
Asch, SM; Chan, K; Clark, JA; Gifford, AL; Groessl, EJ; Hanchate, AD; Ho, SB; Lai, MN; Wong, JB	1
Aggarwal, J; Bayliss, M; Donepudi, M; Goss, T; Martin, M; Vera-Llonch, M; Younossi, Z	1
Aoki, K; Kumada, H; Ohtsuki, M; Sakurai, Y; Sueki, H; Torii, H; Yamada, I	1
Akuta, N; Arase, Y; Fukushima, T; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y	2
Taylor, DR	1
Benhamou, Y; Beumont, M; De Backer, K; De Meyer, S; Ghys, A; Lebray, P; Luo, D; Moussalli, J; Picchio, GR; Ratziu, V	1
Bell, S; Holmes, J; Thompson, A	1
Brown, J; Paladino, JA; Turner, SJ	1
Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL	1
Akuta, N; Hara, T; Hosaka, T; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y	1
Amin, B; Jariwala, S; Patel, P; Rampur, L; Rosenstreich, DL	1
Alraies, MC; Alraiyes, AH; Alsabbagh, ME; Eisa, N	1
Euliano, R; Juneja, M; Lewis, JH; Satoskar, R	1
Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Peytavin, G; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D	1
Blázquez-Pérez, A; Mar, J; San Miguel, R	1
Arakawa, T; Hige, S; Karino, T; Kimura, M; Kuwata, Y; Nakajima, T; Ohmura, T; Ozeki, I; Sato, T; Toyota, J	1
Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J	1
Bichoupan, K; Branch, A; Brinkley, S; Dieterich, D; Martel-Laferrière, V; Perumalswami, P; Posner, S; Schiano, T; Stivala, A; Sulkowski, M	1
Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S	2
Boucher, CA; Broekman, MM; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Lamers, MH; Reesink, HW; van Hoek, B	1
Arends, JE; Dutilh, JC	1
Bau, S; Ferguson, J; Saab, S; Zhou, K	1
Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC	1
Andrade, RJ; García-Samaniego, J	1
Cabezas, J; Crespo, J; Luis Calleja, J; Selmo, J	1
Forns, X; Solà, R	1
Planas, R; Tural, C	1
García, F; Poveda, E	1
Macías, J; Rivero, A	1
Pineda, JA	1
Wang, P; Wang, X; Xu, DH; Yan, SS; Yin, J; Zhang, PJ	1
Inao, M; Mochida, S; Nakayama, N; Sugawara, K	1
Serfaty, L	1
Agarwal, K; Barnabas, A	1
Chiari, E; Cocca, G; Moioli, MC; Morreale, M; Orso, M; Panzeri, C; Puoti, M; Rossotti, R; Travi, G	1
Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Ohnishi, H; Okada, K; Shimizu, M; Takayama, K; Toyoda, K	1
Brulotte, N; Hahn, H; Lee, M	1
Bansal, M; Bichoupan, K; Branch, AD; Crismale, JF; Dieterich, DT; Liu, LU; Martel-Laferrière, V; Odin, JA; Pappas, A; Perumalswami, PV; Schiano, TD; Schonfeld, E; Wyatt, C	1
Amanzada, A; Cameron, S; Goralczyk, AD	1
Aghemo, A; Bitetto, D; Bruno, R; Caraceni, P; Ciancio, A; Coco, B; Marzioni, M; Petta, S; Rendina, M; Valenti, L	1
Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T	1
Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P	1
Chayama, K; Karino, Y; Kawakami, Y; Kumada, H; Suzuki, F; Toyota, J	1
Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S	1
Liu, CJ	1
Abdurakhmanov, D; Colombo, M; DeMasi, R; Fernández, I; Ferreira, PA; Hill, A; Iraqi, W; Läuffer, JM; Lonjon-Domanec, I; Moreno, C; Strasser, SI; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H	1
Aslam, S; Bremer, B; Cobb, B; Cornberg, M; Halfon, P; Luk, K; Maasoumy, B; Manns, MP; Wedemeyer, H	1
Backus, LI; Belperio, PS; Cheung, R; Mole, LA; Shahoumian, TA	1
Baragli, F; Corti, G; Salomoni, E	1
Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM	1
Alberti, A; Colombo, M; Craxì, A; Rizzetto, M	1
Pol, S	1
Akimitsu, N; Salam, KA	1
Ide, T; Kato, K; Kondoh, M; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H; Tsubota, A	1
Agarwal, K; Bertelsen, K; Brown, RS; Buti, M; De Masi, R; De Meyer, S; Hézode, C; Horsmans, Y; Janczewska, E; Luo, D; Nyberg, L; Paraná, R; Rizzetto, M; Sievert, W; Witek, J; Zeuzem, S	1
Goh, C	1
Dusheiko, G; Ferenci, P	1
Abe, H; Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiraga, N; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Ochi, H; Ohishi, W; Ono, A; Takahashi, S; Tsuge, M; Urabe, A; Yokoyama, S	1
Guner, R; Tufan, ZK	1
Cybula, M; Szemraj, J	1
Andreone, P; Coate, B; DeMasi, R; Diago, M; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Lonjon-Domanec, I; Negro, F; Picchio, G; Pol, S; Roberts, S; Serfaty, L; Witek, J; Younossi, Z; Zeuzem, S	1
Aghemo, A; Colombo, M; Falconer, K; Lunghi, G; Sarrazin, C; Susser, S; Vermehren, J; Weiland, O; Zeuzem, S	1
Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Guillaudeau, A; Jacques, J; Legros, R; Loustaud-Ratti, V; Sautereau, D; Vong, C	1
Furusyo, N; Hayashi, J; Hiramine, S; Ikezaki, H; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K	1
Baldini, A; Coate, B; DeMasi, R; Luo, D; Mrus, J; Witek, J; Zeuzem, S	1
Alvarez, H; de la Llana, FG; Domingo, P; Genebat, M; Guardiola, JM; Hernández-Quero, J; Leal, M; Lluch, JF; Marín, J; Mariño, A; Martínez, L; Martínez-Madrid, O; Martínez-Pérez, MA; Ruiz-Mateos, E; Sánchez-Villegas, J; Vera, F	1
Aggarwal, J; Donepudi, M; Goss, TF; Suthoff, E; Vera-Llonch, M; Younossi, Z	1
Booth, CL; Bridge, SH; Dusheiko, G; Garcia-Diaz, A; Haque, T; Irish, D; Jacobs, M; Labbett, W; Macartney, MJ; McCormick, AL; Rosenberg, W; Smith, C; Tanwar, S; Trembling, P; Velazquez, C	1
Gutierrez, JA; Wyles, DL	1
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G	1
Brogan, AJ; Deniz, B; Miller, JD; Rubin, J; Talbird, SE; Thompson, JR	1
Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F	1
Hoshino, T; Kakizaki, S; Koitabashi, E; Kudo, T; Naganuma, A; Okamoto, H; Ryusaki, K; Sakamoto, N; Takagi, H; Uehara, S	1
Azuma, T; Bai, F; Hatazawa, Y; Hayakumo, T; Hayashi, Y; Hirano, H; Hotta, H; Imoto, S; Kim, SR; Miki, A; Minami, A; Momose, K; Rinonce, HT; Saito, M; Seo, Y; Sugano, M; Tani, S; Widasari, DI; Yano, Y; Yoon, S	1
Bechstein, WO; Farnik, H; Ferreiros, N; Galle, PR; Geisslinger, G; Herrmann, E; Kronenberger, B; Labocha, S; Sarrazin, C; Welker, MW; Zeuzem, S; Zimmermann, T	1
Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y	1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N	1
Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS	1
Al-Bawardy, B; Canterbury, K; Charlton, MR; Colby, CL; Gross, JB; Kim, WR; Larson, JJ; Poterucha, JJ; Therneau, TM; Warner, J	1
Sogni, P	1
Assoumou, SA; Barter, DM; DiLorenzo, M; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Salomon, JA; Schackman, BR; Weinstein, MC	1
Nair, S; Waters, B	1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F	1
Fridell, JA; Ghabril, M; Joseph Tector, A; Kwo, PY; Lacerda, MA; Vianna, R	1
Berg, CP; Egetemeyr, DP; Franz, C; Janke-Maier, P; Lauer, UM; Malek, NP; Werner, CR	1
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M	1
Angelillo, IF; Coppola, N; Pisaturo, M; Sagnelli, C; Sagnelli, E	1
Akahoshi, T; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Maehara, Y; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y	1
Aghemo, A; Castaldi, D; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Grassi, E; Rumi, MG; Soffredini, R	1
Chayama, K; Imamura, M	2
Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M	1
Brown, RS; Burton, JR; Dodge, JL; Everson, GT; Levitsky, J; O'Leary, JG; Saxena, V; Stravitz, RT; Terrault, NA; Trotter, JF; Verna, EC	1
Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J	1
Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inui, Y; Kaneko, A; Kasahara, A; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Suzuki, K; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yamada, R; Yoshida, Y; Yoshihara, H	1
Adda, N; Bengtsson, L; Bzowej, NH; DeMasi, R; Dusheiko, GM; Flamm, SL; Fried, MW; George, S; Kieffer, TL; Muir, AJ; Nelson, DR; Reddy, KR; Sullivan, JC; Wright, CI	1
Abe, H; Aizawa, Y; Atsukawa, M; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Nakagawa, A; Sakamoto, C; Shimada, N; Tsubota, A	1
Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH	1
Beumont, M; De Meyer, S; Dierynck, I; Ghys, A; Luo, D; Picchio, G	1
Alves, K; Asmal, M; DeSouza, C; Di Bisceglie, AM; Gane, E; George, S; Jacobson, IM; Kauffman, R; Kieffer, T; Koziel, MJ; Nelson, D; Sulkowski, M; Zhang, EZ	1
Brown, RS; Dove, LM; Fox, AN; Lukose, T; Mentore, K; Olsen, SK; Shetty, K; Terry, N; Verna, EC	1
Joshita, S; Kamijo, A; Katsuyama, Y; Kimura, T; Kiyosawa, K; Kobayashi, M; Komatsu, M; Maruyama, A; Matsumoto, A; Mori, H; Morita, S; Nozawa, Y; Ota, M; Shibata, S; Takamatsu, M; Tanaka, E; Umemura, T; Wada, S; Yoshizawa, K	1
Abe, H; Akamatsu, S; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Miki, D; Murakami, E; Ochi, H; Tsuge, M	1
Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K	1
Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, D; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H	1
Abdurakmonov, D; Abrao Ferreira, P; Colombo, M; DeMasi, R; Fernández, I; Hill, A; Iraqi, W; Lonjon-Domanec, I; Moreno, C; Strasser, S; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H	1
Acero Fernández, D; Ferri Iglesias, MJ; Figa Francesch, M; Hombrados Verde, M; López Nuñez, C; Louvriex Freire, R; Virolés Torrent, S	1
Abdi, AM; Boglione, L; Cardellino, CS; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G	1
Smolić, M; Smolić, R; Vcev, A	1
Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Jacques, J; Loustaud-Ratti, V; Rousseau, A; Sautereau, D; Vong, C	1
Aherfi, S; Borentain, P; Botta-Fridlund, D; Bregigeon, S; Brouqui, P; Colson, P; Dhiver, C; Gérolami, R; Mokhtari, S; Moreau, J; Motte, A; Poizot-Martin, I; Portal, I; Ravaux, I; Ruiz, JM; Solas, C; Stein, A; Tamalet, C	1
Bichoupan, K; Branch, AD; Crismale, J; Dieterich, DT; Gardenier, D; Khaitova, V; Linderman, M; Liu, L; Martel-Laferriere, V; Moskowitz, AJ; Ng, M; Odin, JA; Pappas, A; Perumalswami, PV; Sachs, D; Schiano, TD; Schonfeld, EA; Stivala, A	1
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z	1
Arotçarena, R; Causse, X; Denis, J; Hagège, H; Henrion, J; Lesgourgues, B; Nalet, B; Pariente, A; Rémy, AJ	1
Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inada, M; Inui, Y; Ito, T; Kasahara, A; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H	1
Manos, MM; Murphy, RC; Pauly, MP; Price, JC; Shvachko, VA	1
Berdeaux, G; Bianic, F; Cure, S; de Knegt, RJ; Lamotte, M; van Agthoven, M; van der Kolk, A; Vellopoulou, A	1
Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM	1
Aboulker, JP; Aumaitre, H; Batisse, D; Bertucci, I; Braun, J; Chevaliez, S; Cotte, L; de Truchis, P; Gervais, A; Lacombe, K; Lascoux-Combe, C; Michelet, C; Molina, JM; Morlat, P; Neau, D; Rosa, I; Sogni, P; Valantin, MA; Vincent, C; Vittecoq, D	1
Andreone, P; Conti, F; Vitale, G	1
Falconer, K; Malone, DF; Sandberg, JK; Weiland, O	1
Bruzzi, P; Girardi, E; Ippolito, G; Lanini, S; Mammone, A; Puro, V	1
Bernard, PH; Bernardeschi, C; Duclos-Vallée, JC; Dupin, N; Gressier, L; Hezode, C; Mallet, V; Milpied, B; Ortonne, N; Pol, S; Samuel, D; Valeyrie-Allanore, L; Wallet-Faber, N	1
Blanchard, E; Samaras, K; Vickers, CR	1
Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J	1
Bock, JA; Fairley, KJ; Inverso, NA; Maeng, DD; Pitcavage, JM; Smith, RE; Williams, MS	1
Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Imamura, M; Kan, H; Kawaoka, T; Morio, R; Sasaki, T	1
Andreone, P; Berg, T; De Meyer, S; DeMasi, R; Diago, M; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Lonjon-Domanec, I; Luo, D; Picchio, G; Pol, S; Roberts, S; Younossi, Z; Zeuzem, S	1
Andrade, RJ; Buti, M; Casado, MA; Gros, B; Oyagüez, I; Serra, MA; Turnes, J	1
Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A	1
Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K	1
Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R	1
Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D	1
Firpi, RJ; Hilgenfeldt, E	1
Berg, T; Hamdi, N; Herrmann, E; Lange, C; Müller, T; Perner, D; Sarrazin, C; Susser, S; Zeuzem, S	1
Kawano, A; Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N	1
Asch, SM; Barnett, PG; Dally, SK; Gidwani, R; Goldhaber-Fiebert, JD; Lo, J; Owens, DK	1
Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kouno, M; Kudo, M; Minami, Y; Takita, M; Ueshima, K; Yada, N	1
Arizumi, T; Hagiwara, S; Inoue, T; Kudo, M; Minami, T; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N	1
Bridges, GG; Dorholt, M; Frazee, SG; Henderson, RR; Levin, RJ; Visaria, J	1
Bielsa Marsol, I; Carrascosa Carrillo, JM; Ferrándiz Foraster, C; López Escartin, D; Masnou Ridaura, H; Morillas Cunill, R; Plana Pla, A; Planas Vilà, R; Toro Montecinos, M; Vilavella Rius, M	1
Benjelloun, S; Ezzikouri, S; Inoue, K; Kino, Y; Kohara, M; Matsumori, A; Nishimura, T; Tsukiyama-Kohara, K	1
Bagaglio, S; Della Torre, L; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C	1
Becerro González, I; Carrascosa de Lome, R; de Argila, D; García-Buey, L; Martín Domínguez, V; Villar, K	1
de los Santos-Gil, I; Haubitz, S; Ingiliz, P; Lutz, T; Márquez, M; Mira, JA; Munteanu, D; Neukam, K; Pineda, JA; Rauch, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S	1
Andreone, P; Dammers, E; Fu, M; George, J; Horban, A; Jessner, W; Kurland, D; Lenz, O; Ouwerkerk-Mahadevan, S; Reddy, KR; Scott, J; Stanciu, C; Verbinnen, T; Villamil, FG; Weiland, O; Zeuzem, S; Zoulim, F	1
Dusheiko, G	1
Jones, B; Warren, E; Wright, A	1
Beste, LA; Green, PK; Ioannou, GN	1
Benjamin, S; Botfield, MC; Dimova, RB; Penney, MS; Talal, AH; Zeremski, M	1
Burnevich, ÉZ; Tikhonova, NIu	1
Kim, MJ; Koenigsmann, C; Moorjani, H; Spaulding, AC	1
Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C	1
Andreoni, M; Angelico, M; Antonucci, FP; Aragri, M; Babudieri, S; Ceccherini-Silberstein, F; Cento, V; De Leonardis, F; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gasbarrini, A; Landonio, S; Lenci, I; Magni, CF; Mancon, A; Manunta, A; Micheli, V; Mura, MS; Nicolini, LA; Nosotti, L; Parruti, G; Pellicelli, A; Perno, CF; Rizzardini, G; Sarrecchia, C; Siciliano, M; Taliani, G; Tontodonati, M; Vecchiet, J	1
Abel, L; Albert, ML; Barthe, Y; Bronowicki, JP; Carrat, F; Casrouge, A; Dorival, C; Fontaine, H; Fontanet, A; Gayat, E; Hézode, C; Lagaye, S; Mallet, V; Mottez, E; Pol, S; Sultanik, P; Theodorou, I	1
Färkkilä, M	1
Aboulker, JP; Barrail-Tran, A; Chevaliez, S; Cotte, L; Fournier, I; Lacombe, K; Molina, JM; Taburet, AM; Valantin, MA; Vincent, C	1
Antinori, S; Calvi, E; Cheli, S; Clementi, E; D'Avolio, A; De Nicolò, A; Falvella, FS; Magni, C; Mazzali, C; Milazzo, L; Peri, AM	1
Do, D; Nambudiri, V; Shuster, M	1
Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS	1
Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F	1
Angelico, M; Antonucci, FP; Armenia, D; Babudieri, S; Bellocchi, MC; Bertoli, A; Cacciatore, P; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Di Maio, VC; Fortuna, S; Manunta, A; Navarra, P; Neumann, AU; Parruti, G; Perno, CF; Tontodonati, M; Trave, F; Valenti, F; Vecchiet, J	1
Akamatsu, N; Aoki, T; Harada, N; Hasegawa, K; Ishizawa, T; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Yamaguchi, T	1
Anderson, PL; Baouchi-Mokrane, F; Burton, JR; D'Argenio, DZ; Everson, GT; Hammond, KP; Kiser, JJ; Rower, JE; Urban, TJ; Wu, LS	1
Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L	1
Buti, M; Cloherty, G; De Meyer, S; Dierynck, I; Ghys, A; Janssen, K; Luo, D; Picchio, G; Sarrazin, C; Witek, J	1
Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K	1
Abe, H; Aizawa, Y; Atsukawa, M; Fukuda, T; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A	1
Pan, Q; van der Laan, LJ; Verstegen, MM	1
Mochida, S	1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K	3
Curto, J; Di Yacovo, S; Ferrer, E; Imaz, A; Podzamczer, D; Saumoy, M; Van den Eynde, E; Vila, A	1
Ben-Marzouk-Hidalgo, OJ; Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P	1
Amemiya, F; Enomoto, N; Fukasawa, M; Inoue, T; Komatsu, N; Maekawa, S; Miura, M; Moriishi, K; Muraoka, M; Nakayama, Y; Sakamoto, M; Sato, M; Sato, T; Suzuki, Y; Takano, S; Tatsumi, A; Uetake, T; Yamaguchi, T; Yamashita, A	1
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D	1
Akiyama, MJ; Cheung, R; Ha, NB; Li, J; Nguyen, MH; Piotrowski, JI; Roytman, MM; Tsai, N; Vo, KP; Vu, VD; Vutien, P; Wantuck, J	1
Akker, Dv; Berry, SM; Broglio, KR; Daar, ES; Detry, MA; Kalsekar, A; Le, T; Lewis, RJ; Quintana, M; Spellberg, B; Yuan, Y	1
Albandea Moreno, C; Bautista Galán, C; Ruiz Arredondo, J; Serrato, AR	1
Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawanaka, H; Kimura, Y; Maehara, Y; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Takeishi, K; Tsujita, E; Uchiyama, H; Yamashita, YI; Yoshizumi, T	1
Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J	1
Furusyo, N; Hayashi, J; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Takayama, K	1
Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M	1
Abravanel, F; Alain, S; André-Garnier, E; Baazia, Y; Besse, B; Bouvet, D; Bouvier-Alias, M; Brochot, E; Caporossi, A; David-Tchouda, S; Duverlie, G; Fleury, H; Gaudy-Graffin, C; Gouriou, S; Gozlan, J; Guivarch, M; Haïm-Boukobza, S; Halfon, P; Hantz, S; Henquell, C; Lada, O; Lagathu, G; Larrat, S; LeGuillou-Guillemette, H; Mackiewicz, V; Margier, J; Maylin, S; Mirand, A; Mohamed, S; Morand, P; Mourez, T; Pawlotsky, JM; Pivert, A; Plantier, JC; Pronier, C; Ramière, C; Roque-Afonso, AM; Scholtes, C; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S; Velay, A	1
Ho, S; Mehnert, A; Pacou, M; Pettré, S; Pisini, M; Taieb, V; Ustianowski, A; Van Sanden, S	1
Aksoz, S; Ay, N; Baysal, B; Danis, R; Kaya, S	1
Broquetas, T; Calleja, JL; Campillo, A; Carrión, JA; de la Revilla, J; Forns, X; Lens, S; Londoño, MC; Mariño, Z; Perello, C; Sánchez-Tapias, JM; Urbano-Ispizua, Á	1
Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Shimada, N; Tsubota, A	1
Ikeda, H; Kamijo-Ikemori, A; Kimura, K; Matsui, K; Okuse, C; Shibagaki, Y; Sugaya, T; Yasuda, T	1
Afdhal, NH; Rourke, M; Sethi, N; Sethi, S; Tapper, EB; Vong, A	1
Neyts, J; Paeshuyse, J; Vliegen, I; Zhong, W	1
Tornai, I	1
Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M	1
Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S	1
Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V	1
Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y	1
Ianna, EA; Jones, TL; Reeves, GE; Tran, HA	1
Arain, A; Bastens, B; Bourgeois, S; Bruckers, L; Buntinx, F; d'Heygere, F; de Galocsy, C; Deltenre, P; Francque, S; George, C; Henrion, J; Janssens, F; Laleman, W; Mathei, C; Moreno, C; Nevens, F; Robaeys, G; Van Overbeke, L; Van Vlierberghe, H; Verrando, R	1
Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Fatiguso, G; Mohamed Abdi, A	1
Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V	1
Alshuth, U; Böker, K; Buggisch, P; Christensen, S; Hofmann, WP; Hüppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Schott, E	1
Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R	1
Capobianchi, MR; Castiglione, F; D'Offizi, G; Garbuglia, AR; Lapa, D; Lionetti, R; Montalbano, M; Paci, P; Taibi, C; Visco-Comandini, U	2
Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F	1
Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T	1
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H	1
Bartels, DJ; Garg, V; Haseltine, EL; Kieffer, TL; Kimko, H; Luo, H; Tolsma, J	1
Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M	1
Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M	1
Cockerham-Colas, L; Heo, M; Litwin, AH; Reynoso, S; Roose, RJ; Soloway, IJ; Tenore, C	1
Boonstra, A; de Knegt, RJ; Janssen, HL; Spaan, M; van Oord, GW	1
Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S	1
Bieńkowska-Szewczyk, K; Chmielewska, AM; Król, E; Rychłowska, M; Solarz, K	1
Augustyniak, K; Berak, H; Dobracka, B; Dobracki, W; Dudziak, M; Flisiak, R; Horban, A; Janczewska, E; Jurczyk, K; Kozielewicz, D; Kryczka, W; Lapinski, T; Librant-Suska, M; Lojewski, W; Musialik, J; Olszok, I; Pisula, A; Postawa-Klosińska, B; Ruszala, A; Wroblewski, J; Zarebska-Michaluk, D	1
Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G	1
Akpo, EI; Kleintjens, J; Sbarigia, U; Wan, G	1
Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F	1
Akiyama, T; Eguchi, Y; Ide, Y; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kumagai, T; Mizuta, T; Otsuka, T; Ozaki, I; Yanagita, K; Yasutake, T	1
Durant, J; Girard, PM; González-García, J; Grinsztejn, B; Horban, A; Janssen, K; Lathouwers, E; Montes, ML; Nelson, M; Ortega-Gonzalez, E; Ouwerkerk-Mahadevan, S; Rivero, A; Sasadeusz, J; Witek, J; Zakharova, N	1
Dybowska, D; Karwowska, K; Kozielewicz, D; Wietlicka-Piszcz, M	1
Bani-Sadr, F; Dabis, F; Gilbert, C; Loko, MA; Morlat, P; Neau, D; Rosenthal, E; Salmon, D; Simon, A; Valantin, MA; Wittkop, L	1
Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y	1
Abenavoli, L; Camera, S; Claar, E; Coppola, C; Coppola, N; De Luna, A; Federico, A; Gentile, I; Granata, R; Masarone, M; Morisco, F; Persico, M; Precone, D; Rosato, V; Salomone-Megna, A; Tartaglione, MT	1
Adeyi, O; Chen, L; Cotler, SJ; Deneke, MG; Duarte-Rojo, A; Feld, JJ; Fischer, SE; Malespin, M; McGilvray, ID; Selzner, N; Zita, D	1
Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X	1
Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H	1
Akhan, S; Aynioglu, A; Sargin Altunok, E; Sayan, M	1
Nishimura, T	1
Dolar, E; Gülten, M; Gürel, S; Kiyici, M; Nak, SG; Pekgöz, M	1
Applegate, T; Dore, GJ; Grebely, J; Haber, P; Hellard, M; Iser, D; Lloyd, A; Maire, L; Martinello, M; Matthews, GV; Petoumenos, K; Sasadeusz, J; Shaw, D; Thompson, A; Yeung, B	1
Arends, JE; Burger, DM; Friederich, P; Koek, GH; Lieveld, FI; Siersema, PD; van Erpecum, KJ; van Meer, S; van Nieuwkerk, KM; van Vlerken, LG	1
Horn, M; Horvath, A; Jurse, P; Leber, B; Lemesch, S; Posch, A; Schmerböck, B; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A; Tawdrous, M; Wuensch, G; Zettel, G	1
Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G	1
Alshuth, U; Buggisch, P; Galle, PR; Grimm, D; Hueppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Zimmermann, T	1
Fukuda, Y; Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Koike, K; Matsumoto, N; Matsunaga, K; Nakahara, K; Noguchi, Y; Okuse, C; Shigefuku, R; Shima, J; Suzuki, M; Watanabe, T; Yamamoto, H; Yasuda, H; Yotsuyanagi, H	1
Abdurakhmanov, D; Baruch, Y; Bruck, R; Diago, M; Ferenci, P; Flisiak, R; Gadano, A; Hughes, EA; Jacobson, I; Janczewska, E; Knysz, B; Kopit, J; Lueth, S; McPhee, F; Michener, T; Noviello, S; Safadi, R; Shafran, S; Thabut, D; Thompson, AJ; Yin, PD; Zarebska-Michaluk, D; Zeuzem, S; Zignego, AL	1
Diago, M; Peño, L; Plana, L; Urquijo, JJ	1
Arai, M; Haga, Y; Imazeki, F; Kanda, T; Mikami, S; Nakamoto, S; Nakamura, M; Ogasawara, S; Sasaki, R; Tawada, A; Yasui, S; Yokosuka, O	1
Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C	1
Botta, D; Gaudy-Marqueste, C; Grob, JJ; Lorcy, S; Mancini, J; Oulies, V; Portal, I; Quiles, N; Richard, MA	1
Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N	1
Assy, N; Dong, Y; Flisiak, R; Gadano, A; Kao, JH; Kawazoe, S; Kumada, H; Lee, KS; Portsmouth, S; Srinivasan, S; Xu, D; Znoyko, O; Zwirtes, R	1
Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X	1
Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP	1
Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O	1
Fagundes, RN; Ferreira, LE; Pace, FH	1
Abu Freha, N; Ben Yakov, G; Dizingof, V; Etzion, O; Fich, A; Monitin, S; Montano, D; Mushkalo, A; Shwarts, D; Sikuler, E; Takchick, A; Zilberman, D	1
Chadwick, PW; Heymann, WR	1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y	1
Anthony, DD; Bonomo, RA; Chandar, AK; Compan, A; Davitkov, P; Falck-Ytter, Y; Gideon, C; Hirsch, A; Silveira, MG; Smith, S	1
Arenas, J; Cheinquer, H; Dong, Y; Flisiak, R; Nikitin, I; Rana, K; Shiffman, M; Srinivasan, S	1
Chida, T; Ito, M; Nakashima, K; Suzuki, T	1
Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM	1
Hmwe, SS; Ide, T; Inoue, T; Kato, K; Kumada, T; Shimada, N; Takaguchi, K; Tanaka, Y; Torimura, T; Toyoda, H; Tsubota, A; Wakita, T	1
Yu, ML	1
Alvarez, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Islam, N; Janjua, NZ; Krajden, M; Ramji, A; Samji, H; Tyndall, M; Wong, J; Yoshida, EM	1
Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H	1
Ide, K; Iketani, R; Kawasaki, Y; Masaki, N	1
Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ	1
Gray, E; Norris, S; O'Leary, A; Pasta, DJ	1
Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E	1
Akutagawa, M; Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H; Yamanaka, M	1
Agrati, C; Bordoni, V; Casetti, R; Ciccosanti, F; Cimini, E; D'Offizi, G; Fimia, G; Lionetti, R; Martini, F; Montalbano, M; Refolo, G; Sacchi, A; Taibi, C; Tumino, N; Turchi, F	1
Ballard, C; Cachay, ER; Colwell, B; Hicks, C; Mathews, WC; Torriani, F	1
Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG	1
Chen, C; Hartigan-O'Connor, DJ; Khalili, M; Lanier, LL; Lu, D; Manos, MM; McCune, JM; Méndez-Lagares, G; Monto, A; Ryan, JC; Segal, MR; Shen, H; Terrault, N	1
Abbott, JC; Boesecke, C; Jagjit Singh, GK; Kaye, S; McClure, MO; Nelson, M; Rockstroh, J	1
Blatt, CR; Carneiro, JMM; Chachá, SGF; Farias, MR; Feltrin, AA; Gomes, LO; Martinelli, ALC; Noblat, LACB; Pereira, LRL; Rodrigues, JPV; Rosa, JAD; Silveira, MPT; Teixeira, MR; Vecchi, MD	1
Borba, HHL; Ferreira, VL; Minowa, E; Pontarolo, R; Rochau, U; Siebert, U; Sroczynski, G; Wiens, A	1
Cazarim, MS; Chachá, SGF; Martinelli, ALC; Pereira, LRL; Rodrigues, JPV	1
Nordien, R; Sonderup, MW; Spearman, CW	1
Krzyzanski, W; Perez-Ruixo, JJ; Vermeulen, A; Woot de Trixhe, X	1
Adianti, M; Aoki-Utsubo, C; Hafid, AF; Hotta, H; Permanasari, AA; Tumewu, L; Wahyuni, TS; Widyawaruyanti, A	1

Reviews

116 review(s) available for ribavirin and telaprevir

Article	Year
[Drugs for hepatitis B and C infection]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1 Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Lamivudine; Mutation; Oligopeptides; Organophosphonates; Proline; Ribavirin; Serine Proteinase Inhibitors	2007
Future treatment options for HCV: double, triple, what is the optimal combination? Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6 Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin	2008
[Antiviral therapy for chronic hepatitis C: current status and perspectives]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:2 Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin; Thiazoles	2010
Treatment of hepatitis C in 2011: what can we expect? Current gastroenterology reports, 2010, Volume: 12, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Forecasting; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin	2010
Safety of small molecules in combination with interferon-based therapy for hepatitis C virus. Expert opinion on drug safety, 2010, Volume: 9, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome	2010
Telaprevir: a new hope in the treatment of chronic hepatitis C? Advances in therapy, 2010, Volume: 27, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome	2010
Telaprevir. Drugs in R&D, 2010, Volume: 10, Issue:3 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Microbial Sensitivity Tests; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Proteins	2010
Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:2 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome	2011
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Signal Transduction; Standard of Care; Virus Replication	2011
Hepatitis in 2010: the dawn of a new era in HCV therapy. Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
[New therapeutic options in chronic hepatitis C virus infection]. Orvosi hetilap, 2011, May-29, Volume: 152, Issue:22 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2011
New treatments for chronic hepatitis C virus infection. Medecine et maladies infectieuses, 2011, Volume: 41, Issue:11 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational	2011
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS (London, England), 2011, Nov-28, Volume: 25, Issue:18 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
An overview of emerging therapies for the treatment of chronic hepatitis C. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. Journal of hepatology, 2012, Volume: 56, Issue:2 Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Skin Diseases	2012
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 2011, Volume: 86, Issue:10 Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir	2011
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Orvosi hetilap, 2011, Dec-11, Volume: 152, Issue:50 Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia	2011
Telaprevir for the treatment of chronic hepatitis C infection. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:12 Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
[New agents for the treatment of hepatitis C]. Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:3 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins	2012
Telaprevir: looking for a sustained virologic response in hepatitis C virus infection. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:11 Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2011
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antiviral therapy, 2011, Volume: 16, Issue:8 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2011
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-01, Volume: 54, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2012
Telaprevir user's guide. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; Hepacivirus; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load	2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment	2012
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load	2012
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult	2012
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure	2012
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load	2012
Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'? Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load	2012
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Disease Eradication; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome	2012
Future treatment of patients with HCV cirrhosis. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load	2012
Hepatitis C virus treatment pre- and post-liver transplantation. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load	2012
Hepatitis C virus-human immunodeficiency virus coinfection. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load	2012
What's new in HCV genotype 2 treatment. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2012
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load	2012
The future for the treatment of genotype 4 chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D	2012
Barriers to hepatitis C treatment. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Refusal; Viral Load	2012
Treatment failure with new hepatitis C drugs. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Phenotype; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure	2012
Antiviral strategies in hepatitis C virus infection. Journal of hepatology, 2012, Volume: 56 Suppl 1 Topics: Antiviral Agents; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins	2012
IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2 Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2011
Telaprevir for the treatment of hepatitis C. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin	2012
Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Neoplasms; North America; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Viral Load	2012
Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs, 2012, Mar-26, Volume: 72, Issue:5 Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load	2012
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current opinion in virology, 2011, Volume: 1, Issue:6 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2011
Hepatitis C therapy update. Current opinion in gastroenterology, 2012, Volume: 28, Issue:3 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors	2012
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Current opinion in organ transplantation, 2012, Volume: 17, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load	2012
New virologic tools for management of chronic hepatitis B and C. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Point-of-Care Systems; Polyethylene Glycols; Proline; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome	2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Tract; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome	2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome	2012
[Anti HCV drugs--ribavirin, telaprevir]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin	2012
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:9 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; United States	2012
[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively]. Przeglad epidemiologiczny, 2012, Volume: 66, Issue:1 Topics: Antiviral Agents; Carrier Proteins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Oligopeptides; Poland; Proline; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins	2012
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:10 Topics: Antiviral Agents; Drug Combinations; France; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors	2012
[Chronic hepatitis C: improved cure rates with new approved medications]. MMW Fortschritte der Medizin, 2012, Jun-21, Volume: O 154 Suppl 2 Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
Telaprevir: pharmacokinetics and drug interactions. Antiviral therapy, 2012, Volume: 17, Issue:7 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ketoconazole; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins	2012
A new era in the treatment of chronic hepatitis C infection. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2013
Interferon stimulated genes and hepatitis C virus infection. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012, Volume: 32, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2012
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:2 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Telaprevir for chronic hepatitis C virus infection. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors	2013
Management of the transplant recipient with chronic hepatitis C. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferons; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Care; Preoperative Care; Proline; Ribavirin; Serine Proteinase Inhibitors	2013
Future perspectives: towards interferon-free regimens for HCV. Antiviral therapy, 2012, Volume: 17, Issue:6 Pt B Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2012
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. Journal of gastroenterology, 2013, Volume: 48, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Oligopeptides; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin	2013
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2012
The role of resistance in HCV treatment. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mutation; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2012
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PloS one, 2012, Volume: 7, Issue:12 Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin	2012
Optimal treatment with telaprevir for chronic HCV infection. Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1 Topics: Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins	2013
Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis. Die Pharmazie, 2012, Volume: 67, Issue:12 Topics: Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2012
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clinical therapeutics, 2013, Volume: 35, Issue:2 Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin	2013
Anemia management in patients with chronic viral hepatitis C. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2 Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2013
The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:6 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Oligopeptides; Polyethylene Glycols; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Risk; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load; Viremia	2013
Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clinical drug investigation, 2013, Volume: 33, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Odds Ratio; Oligopeptides; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Emerging therapeutic targets for hepatitis C virus infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin	2013
[Progress in hepatitis C treatment]. Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia	2013
[Telaprevir-induced pityriasis rubra pilaris]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:5 Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Biopsy; Drug Eruptions; Drug Therapy, Combination; Eosinophilia; Eosinophils; Hepacivirus; Hepatitis C, Chronic; Histamine Antagonists; Humans; Interferon-alpha; Keratinocytes; Lymphocytes; Middle Aged; Oligopeptides; Pityriasis Rubra Pilaris; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin; Viral Nonstructural Proteins	2013
Evolution of cell culture systems for HCV. Antiviral therapy, 2013, Volume: 18, Issue:3 Pt B Topics: Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Cultivation; Virus Replication	2013
Protease inhibitors for hepatitis C: economic implications. PharmacoEconomics, 2013, Volume: 31, Issue:9 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality of Life; Recombinant Proteins; Ribavirin	2013
[Biochemical and pharmacological features of telaprevir]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Administration, Oral; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Food-Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Humans; Inactivation, Metabolic; Interferons; Interleukins; Intestinal Absorption; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication	2013
[Telaprevir in treatment-naïve patients with HCV monoinfection]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Young Adult	2013
[Telaprevir in HCV-monoinfected patients with failure to prior treatment]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome	2013
[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Drug Eruptions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Medical Futility; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Stevens-Johnson Syndrome; Viral Load	2013
[Telaprevir resistance]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication	2013
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Severity of Illness Index	2013
[Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:7 Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Treatment Outcome	2013
Optimizing DAA management in daily practice. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Checklist; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Medication Adherence; Oligopeptides; Patient Education as Topic; Polyethylene Glycols; Proline; Ribavirin	2013
Management of anaemia and other treatment complications. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin	2013
Treatment of chronic hepatitis C virus infection after liver transplantation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention	2013
Optimizing treatment in HIV/HCV coinfection. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin	2013
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients. BMC gastroenterology, 2013, Oct-14, Volume: 13 Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2014
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1 Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Virus Activation	2014
[Hepatitis C virus: 25 years-old, the end?]. Medecine sciences : M/S, 2013, Volume: 29, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2013
Hepatitis C virus NS3 inhibitors: current and future perspectives. BioMed research international, 2013, Volume: 2013 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins	2013
[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections]. Postepy higieny i medycyny doswiadczalnej (Online), 2013, Dec-11, Volume: 67 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polymorphism, Genetic; Prognosis; Proline; Protease Inhibitors; Regulatory Sequences, Nucleic Acid; Ribavirin; Treatment Outcome	2013
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. Journal of viral hepatitis, 2014, Volume: 21, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Species Specificity; Treatment Outcome	2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clinical pharmacokinetics, 2014, Volume: 53, Issue:5 Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PloS one, 2014, Volume: 9, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2014
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors. Przeglad epidemiologiczny, 2013, Volume: 67, Issue:4 Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin	2013
[Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Education, Medical, Continuing; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides	2014
Treating hepatitis C in the elderly: the future is near? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2014
Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach. The new microbiologica, 2014, Volume: 37, Issue:3 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin; Young Adult	2014
Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:11 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2014
Hepatitis C management in post-transplant patients. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load	2015
[New drugs for hepatitis C]. Duodecim; laaketieteellinen aikakauskirja, 2014, Volume: 130, Issue:18 Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferons; Oligopeptides; Recurrence; Ribavirin; Risk Factors	2014
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. Orvosi hetilap, 2015, Mar-01, Volume: 156, Issue:9 Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome	2015
Gene therapies for hepatitis C virus. Advances in experimental medicine and biology, 2015, Volume: 848 Topics: Animals; Antiviral Agents; Drug Delivery Systems; Genetic Therapy; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Ribavirin; RNA Interference; RNA, Small Interfering	2015
Management of post transplant hepatitis C in the direct antiviral agents era. Hepatology international, 2015, Volume: 9, Issue:2 Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins	2015
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. Journal of comparative effectiveness research, 2015, Volume: 4, Issue:2 Topics: Algorithms; Antiviral Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2015
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice]. Gastroenterologia y hepatologia, 2014, Volume: 37 Suppl 1 Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors	2014
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus. Journal of medical economics, 2015, Volume: 18, Issue:10 Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Bibliographic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Viral Load	2015
[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy]. Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
[Novel methods of hepatitis C treatment and prevention]. Postepy higieny i medycyny doswiadczalnej (Online), 2015, Aug-19, Volume: 69 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Simeprevir	2015
Advances in drug development for hepatitis C. Uirusu, 2015, Volume: 65, Issue:2 Topics: Antiviral Agents; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Viral Nonstructural Proteins	2015
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8 Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load	2017
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC gastroenterology, 2017, Nov-23, Volume: 17, Issue:1 Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine	2017

Trials

85 trial(s) available for ribavirin and telaprevir

Article	Year
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:1 Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Cell Line; Crystallography, X-Ray; Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Oligopeptides; Phenotype; Viral Nonstructural Proteins; Virus Replication	2008
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Journal of hepatology, 2008, Volume: 49, Issue:2 Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2008
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18 Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult	2009
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18 Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult	2009
Telaprevir for previously treated chronic HCV infection. The New England journal of medicine, 2010, Apr-08, Volume: 362, Issue:14 Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Exanthema; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Failure; Viral Load; Young Adult	2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology, 2011, Volume: 140, Issue:2 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2011
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. Journal of gastroenterology, 2011, Volume: 46, Issue:7 Topics: Anemia; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genomic Structural Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2011
Telaprevir for retreatment of HCV infection. The New England journal of medicine, 2011, Jun-23, Volume: 364, Issue:25 Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Serine Proteinase Inhibitors; Viral Load; Young Adult	2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology, 2011, Volume: 141, Issue:3 Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Single-Blind Method; Treatment Outcome	2011
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. Journal of hepatology, 2012, Volume: 56, Issue:1 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2012
Response-guided telaprevir combination treatment for hepatitis C virus infection. The New England journal of medicine, 2011, Sep-15, Volume: 365, Issue:11 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Exanthema; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult	2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Young Adult	2011
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 53, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2012
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Journal of viral hepatitis, 2012, Volume: 19, Issue:2 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin Diseases; Treatment Outcome; Withholding Treatment	2012
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut, 2012, Volume: 61, Issue:10 Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult	2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6 Topics: Antiviral Agents; Chi-Square Distribution; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kaplan-Meier Estimate; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure	2012
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. Journal of acquired immune deficiency syndromes (1999), 2012, Nov-01, Volume: 61, Issue:3 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin	2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. Journal of hepatology, 2013, Volume: 58, Issue:3 Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Salvage Therapy; Treatment Failure	2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Journal of hepatology, 2013, Volume: 58, Issue:5 Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Failure; Treatment Outcome; Young Adult	2013
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PloS one, 2013, Volume: 8, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Platelet Count; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome	2013
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Journal of hepatology, 2013, Volume: 59, Issue:2 Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2013
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:5 Topics: Aged; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis	2014
Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. Journal of viral hepatitis, 2013, Volume: 20, Issue:6 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, Protein; Treatment Outcome; Viral Nonstructural Proteins	2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Journal of hepatology, 2013, Volume: 59, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load	2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of internal medicine, 2013, Jul-16, Volume: 159, Issue:2 Topics: Adult; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:7 Topics: Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2013
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. Journal of hepatology, 2013, Volume: 59, Issue:4 Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors	2013
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2 Topics: Adult; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genotype; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Time Factors; Viral Load	2013
Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. The Journal of dermatology, 2013, Volume: 40, Issue:8 Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Young Adult	2013
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. The Journal of infectious diseases, 2013, Volume: 208, Issue:6 Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult	2013
Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:2 Topics: Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2014
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9 Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome	2013
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:2 Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir	2014
Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antiviral therapy, 2014, Volume: 19, Issue:3 Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2014
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut, 2014, Volume: 63, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome	2014
Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. Journal of gastroenterology, 2014, Volume: 49, Issue:11 Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult	2014
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology, 2014, Volume: 146, Issue:3 Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Nausea; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2014
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. Journal of gastroenterology, 2014, Volume: 49, Issue:12 Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult	2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6 Topics: Adult; Aged; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome	2013
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. Journal of hepatology, 2014, Volume: 60, Issue:6 Topics: Adult; Aged; Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult	2014
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of viral hepatitis, 2015, Volume: 22, Issue:1 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Efficiency; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome	2015
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (London, England), 2014, Jan-28, Volume: 28, Issue:3 Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome; United States	2014
Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clinical transplantation, 2014, Volume: 28, Issue:6 Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Risk Factors; Viral Load	2014
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:9 Topics: Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Splenectomy; Thrombocytopenia; Treatment Outcome; Young Adult	2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. Journal of gastroenterology, 2015, Volume: 50, Issue:3 Topics: Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2015
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology journal, 2014, May-16, Volume: 11 Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Ribavirin; Treatment Failure; Young Adult	2014
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:7 Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclohexanols; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiophenes; Treatment Outcome; Viral Nonstructural Proteins; Young Adult	2014
High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2 Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load	2015
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antiviral therapy, 2015, Volume: 20, Issue:2 Topics: 2-Naphthylamine; Antiviral Agents; Biological Assay; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Oligopeptides; Polyethylene Glycols; Proline; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Uracil; Viral Load	2015
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. Journal of hepatology, 2014, Volume: 61, Issue:5 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult	2014
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Antiviral research, 2014, Volume: 109 Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isomerism; Male; Middle Aged; Oligopeptides; Ribavirin	2014
eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Age Factors; Antiviral Agents; ErbB Receptors; Hepatitis C; Humans; Interferon-alpha; Kidney; Linear Models; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors	2015
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12 Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2 Topics: Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Lipoproteins, LDL; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Treatment Outcome	2015
Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:22 Topics: Antiviral Agents; Appetite; Body Weight; Depression; Drug Therapy, Combination; Female; Genotype; Ghrelin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome; Weight Loss	2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult	2015
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. The Journal of infectious diseases, 2015, Jun-01, Volume: 211, Issue:11 Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Young Adult	2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7 Topics: Aged; Antiviral Agents; Area Under Curve; beta 2-Glycoprotein I; Biomarkers; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
Telaprevir enhances ribavirin-induced anaemia through renal function impairment. Antiviral therapy, 2015, Volume: 20, Issue:5 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin	2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:7 Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult	2015
Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients. Bioscience trends, 2014, Volume: 8, Issue:6 Topics: Anemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Japan; Leukopenia; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transplant Recipients; Treatment Outcome	2014
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4 Topics: Adult; Antiviral Agents; Body Weight; Erythrocytes; Female; Half-Life; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Models, Statistical; Oligopeptides; Phosphorylation; Population; Ribavirin; Sex Characteristics	2015
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6 Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2015
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:6 Topics: Adult; Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Ribavirin; Tandem Mass Spectrometry	2015
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World journal of gastroenterology, 2015, Apr-21, Volume: 21, Issue:15 Topics: Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Down-Regulation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2015
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:7 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2015
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PloS one, 2015, Volume: 10, Issue:7 Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load	2015
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:1 Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult	2016
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. The Journal of infection, 2015, Volume: 71, Issue:6 Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult	2015
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs in R&D, 2015, Volume: 15, Issue:4 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir	2015
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:1 Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult	2016
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PloS one, 2016, Volume: 11, Issue:1 Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2016
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Antiviral therapy, 2016, Volume: 21, Issue:5 Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure	2016
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:5 Topics: Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Ribavirin	2016
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PloS one, 2016, Volume: 11, Issue:3 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Elastase; Male; Middle Aged; Neutrophils; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome	2016
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Smoking; Time Factors; Treatment Outcome; Viral Load; Young Adult	2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World journal of gastroenterology, 2016, Mar-28, Volume: 22, Issue:12 Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult	2016
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:11 Topics: Adult; Aged; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Young Adult	2016
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PloS one, 2016, Volume: 11, Issue:10 Topics: Anemia; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Oligopeptides; Proline; Ribavirin; Severity of Illness Index; Treatment Outcome	2016
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult	2016
Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:2 Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; North America; Oligopeptides; Phenotype; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome	2018
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PloS one, 2017, Volume: 12, Issue:1 Topics: Aged; Antiviral Agents; Cell Line; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transfection; Treatment Outcome; Viral Load; Viremia	2017
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PloS one, 2017, Volume: 12, Issue:5 Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins	2017
Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure. HIV clinical trials, 2018, Volume: 19, Issue:2 Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Genotype; Germany; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mutant Proteins; Mutation, Missense; Oligopeptides; Prevalence; Ribavirin; Treatment Failure; United Kingdom; Viral Nonstructural Proteins	2018
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. Revista do Instituto de Medicina Tropical de Sao Paulo, 2018, Volume: 60 Topics: Antiviral Agents; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin	2018

Other Studies

254 other study(ies) available for ribavirin and telaprevir

Article	Year
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. The Journal of biological chemistry, 2007, Aug-03, Volume: 282, Issue:31 Topics: Amino Acid Sequence; Antiviral Agents; Arginine; Crystallography, X-Ray; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Models, Molecular; Molecular Sequence Data; Oligopeptides; Phenotype; Polyethylene Glycols; Protein Conformation; Protein Structure, Tertiary; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2007
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Replicon; Ribavirin; Viral Nonstructural Proteins	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines. European journal of medicinal chemistry, 2013, Volume: 69 Topics: Aniline Compounds; Antiviral Agents; Dose-Response Relationship, Drug; Enterovirus; Hepacivirus; Microbial Sensitivity Tests; Molecular Structure; Oxazoles; Structure-Activity Relationship	2013
2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. Journal of medicinal chemistry, 2020, 06-11, Volume: 63, Issue:11 Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Dogs; Drug Design; Drug Resistance, Viral; Female; Half-Life; Hepacivirus; Humans; Male; Mice; Mutation; Nitriles; Rats; Structure-Activity Relationship; Virus Replication	2020
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Future therapies for hepatitis C: where do we go from here? Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4, Issue:2 Topics: Antiviral Agents; Biomedical Research; Drug Design; Hepatitis C; Humans; Oligopeptides; Pyrimidine Nucleosides; Recombinant Fusion Proteins; Ribavirin; Toll-Like Receptors	2007
ADVANCE study begins enrollment. AIDS patient care and STDs, 2008, Volume: 22, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral	2008
Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. Journal of hepatology, 2008, Volume: 49, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2008
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib	2008
Telaprevir phase 3 realize trial starts. AIDS patient care and STDs, 2008, Volume: 22, Issue:10 Topics: Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin	2008
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. Current gastroenterology reports, 2009, Volume: 11, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication	2009
A step forward in therapy for hepatitis C. The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18 Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load	2009
Telaprevir for chronic HCV infection. The New England journal of medicine, 2009, Jul-30, Volume: 361, Issue:5 Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2009
Hepatitis C drug development at a crossroads. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2009
Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!". Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:5 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome	2009
Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Journal of medical virology, 2010, Volume: 82, Issue:4 Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult	2010
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:2 Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Recombinant Proteins; Remission Induction; Ribavirin; Viral Core Proteins; Young Adult	2010
Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology (Basel, Switzerland), 2010, Volume: 221, Issue:4 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Eruptions; Drug Therapy, Combination; Dyspnea; Eosinophilia; Exanthema; Female; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome	2010
Big changes are coming in hepatitis C. Current gastroenterology reports, 2011, Volume: 13, Issue:1 Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2011
Adding telaprevir improves cure rate in patient with HCV infection. AIDS patient care and STDs, 2010, Volume: 24, Issue:12 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2010
The role of triple therapy in HCV genotype 1-experienced patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2 Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin	2011
The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology, 2011, Volume: 140, Issue:3 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2011
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology, 2012, Volume: 55, Issue:6 Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Young Adult	2012
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. The Journal of infectious diseases, 2011, Jul-01, Volume: 204, Issue:1 Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Predictive Value of Tests; Pyrophosphatases; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins	2011
Therapeutics: new drugs hit the target. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Simeprevir; Sulfonamides	2011
Boceprevir for chronic HCV genotype 1 infection. The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load	2011
Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. The Medical letter on drugs and therapeutics, 2011, Jul-25, Volume: 53, Issue:1369 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antiviral therapy, 2011, Volume: 16, Issue:5 Topics: Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Time Factors; Viral Load	2011
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:9 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drug Interactions; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Serine Proteases; Serine Proteinase Inhibitors; Viral Proteins	2011
[New triple therapy in chronic hepatitis C. Increased patient chances]. MMW Fortschritte der Medizin, 2011, Sep-29, Volume: 153, Issue:39 Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; RNA, Viral	2011
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nature biotechnology, 2011, Nov-08, Volume: 29, Issue:11 Topics: Animals; Clinical Trials as Topic; Drug Discovery; Genotype; Hepacivirus; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Interferon-alpha; Mice; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
[Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4 Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6 Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; United Kingdom; Viral Load	2012
[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:5 Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10 Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome	2012
[Current indications for triple therapy in hepatitis C virus infection]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects. Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Secondary Prevention; United States	2013
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PloS one, 2012, Volume: 7, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2012
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American journal of gastroenterology, 2012, Volume: 107, Issue:5 Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Risk Factors	2012
Genetic factors and hepatitis C virus infection. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Antiviral Agents; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome	2012
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:9 Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load	2012
New genetic discoveries and treatment for hepatitis C. JAMA, 2012, May-09, Volume: 307, Issue:18 Topics: Antiviral Agents; DNA, Viral; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Proline; Recombinant Proteins; Ribavirin	2012
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. Journal of medical virology, 2012, Volume: 84, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Virology	2012
Effect of discounting on estimation of benefits determined by hepatitis C treatment. World journal of gastroenterology, 2012, Jun-21, Volume: 18, Issue:23 Topics: Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin	2012
Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. Southern medical journal, 2012, Volume: 105, Issue:8 Topics: Antiviral Agents; Black or African American; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Research Subjects; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Failure	2012
Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome	2012
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut, 2012, Volume: 61, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure	2012
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:12 Topics: Aged; Antiviral Agents; Biomarkers; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2012
Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:1 Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2013
[Treatment of chronic hepatitis viral C: new associations]. Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:6 Pt 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2013
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Journal of hepatology, 2013, Volume: 58, Issue:2 Topics: Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. Infectious disease clinics of North America, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load	2012
Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 56, Issue:2 Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2013
[Medicines for liver diseases; interferon preparations and anti-hepatitis virus agents]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 6 Topics: Antiviral Agents; Drug Combinations; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2012
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:2 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Medical Futility; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load	2013
Hepatitis C in 2012. South Dakota medicine : the journal of the South Dakota State Medical Association, 2012, Volume: 65, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Gastroenterology; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin	2012
Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin	2012
[Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:12 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2012
Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy? Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2 Topics: Adult; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome	2013
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:4 Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Treatment Outcome; Virus Activation	2013
Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:4 Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Pancreatitis; Panniculitis; Ribavirin; Skin	2013
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8 Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load	2013
Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. Journal of medical virology, 2013, Volume: 85, Issue:6 Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome	2013
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8 Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States	2013
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Hepacivirus; Hepatitis; Humans; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Tandem Mass Spectrometry	2013
Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral research, 2013, Volume: 99, Issue:2 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral	2013
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:11 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Expectancy; Male; Middle Aged; Oligopeptides; Proline; Quality of Life; Ribavirin; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health	2013
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. Journal of clinical microbiology, 2013, Volume: 51, Issue:9 Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Prognosis; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2013
Hepatitis C--an update. Australian family physician, 2013, Volume: 42, Issue:7 Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load	2013
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. AIDS (London, England), 2013, Nov-28, Volume: 27, Issue:18 Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Severity of Illness Index; United States; Withholding Treatment	2013
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. Journal of medical virology, 2013, Volume: 85, Issue:10 Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Oligopeptides; Pilot Projects; Ribavirin; Treatment Outcome	2013
DRESS syndrome with suspected Strongyloides infection in a patient treated for hepatitis C. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:2 Topics: Animals; Antiparasitic Agents; Antiviral Agents; Drug Hypersensitivity; Eosinophilia; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Ivermectin; Male; Middle Aged; Oligopeptides; Prednisone; Recombinant Proteins; Ribavirin; Strongyloides; Strongyloidiasis; Syndrome	2013
Chronic hepatitis C therapy: a rare complication revisited. BMJ case reports, 2013, Jul-26, Volume: 2013 Topics: Administration, Cutaneous; Antiviral Agents; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Recombinant Proteins; Ribavirin	2013
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Digestive diseases and sciences, 2013, Volume: 58, Issue:11 Topics: Adult; Aged; Antiviral Agents; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polypharmacy; Proline; Retrospective Studies; Ribavirin; Viral Load	2013
Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. AIDS (London, England), 2013, Oct-23, Volume: 27, Issue:16 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome; Viral Load	2013
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. PharmacoEconomics, 2013, Volume: 31, Issue:10 Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain	2013
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. Journal of viral hepatitis, 2014, Volume: 21, Issue:5 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Serum	2014
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:36 Topics: Adult; Antiviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load	2013
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV medicine, 2014, Volume: 15, Issue:2 Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Viral Load	2014
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. Journal of medical economics, 2014, Volume: 17, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin	2014
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. The Netherlands journal of medicine, 2013, Volume: 71, Issue:7 Topics: Adult; Antiviral Agents; Drug Interactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2013
Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient. The Netherlands journal of medicine, 2013, Volume: 71, Issue:7 Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Withholding Treatment	2013
Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection. Journal of clinical gastroenterology, 2014, Volume: 48, Issue:6 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors	2014
New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:9 Suppl 4 Topics: Antiviral Agents; Community Health Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Retrospective Studies; Ribavirin; Viral Load	2013
[Conclusions]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin	2013
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. Journal of gastroenterology, 2014, Volume: 49, Issue:2 Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retinal Diseases; Ribavirin	2014
Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC. Digestive diseases and sciences, 2014, Volume: 59, Issue:4 Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load	2014
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:7 Topics: Anemia; Diabetes Mellitus, Type 2; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics, Nonparametric	2014
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting	2014
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. Journal of medical economics, 2014, Volume: 17, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Resources; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Analysis	2014
Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role? Pharmacology, 2013, Volume: 92, Issue:5-6 Topics: Adult; Antiviral Agents; Carrier Proteins; Drug Interactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Seizures; Viral Nonstructural Proteins	2013
Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. Journal of clinical microbiology, 2014, Volume: 52, Issue:1 Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Japan; Male; Middle Aged; Molecular Sequence Data; Oligopeptides; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Young Adult	2014
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viremia	2014
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Antiviral Agents; Cohort Studies; Comparative Effectiveness Research; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Thrombocytopenia; United States; Veterans	2014
Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 19 Topics: Administration, Oral; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome	2014
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:2 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2014
The dilemma for patients with chronic hepatitis C: treat now or warehouse? Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Antiviral Agents; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors; Watchful Waiting	2014
Hepatitis C treatment and alopecia totalis. The journal of investigative dermatology. Symposium proceedings, 2013, Volume: 16, Issue:1 Topics: Alopecia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment	2013
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of hepatology, 2014, Volume: 60, Issue:2 Topics: Antiviral Agents; Contraindications; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin	2014
Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis. Gut, 2014, Volume: 63, Issue:7 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2014
Telaprevir use in a chronic hepatitis C patient with hemophilia. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome	2014
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. Journal of hepatology, 2014, Volume: 60, Issue:5 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Viral Load; Viremia	2014
Severe renal impairment during triple therapy with telaprevir. Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:4 Topics: Acute Kidney Injury; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index	2014
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:5 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2014
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral research, 2014, Volume: 104 Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult	2014
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. Antiviral research, 2014, Volume: 105 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viral Nonstructural Proteins	2014
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. Journal of viral hepatitis, 2014, Volume: 21, Issue:4 Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Treatment Outcome	2014
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PloS one, 2014, Volume: 9, Issue:3 Topics: Anemia; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Economic; Multicenter Studies as Topic; Oligopeptides; Outcome Assessment, Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin	2014
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. Journal of viral hepatitis, 2014, Volume: 21, Issue:9 Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load	2014
Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV. Hepato-gastroenterology, 2013, Volume: 60, Issue:127 Topics: Antiviral Agents; Biomarkers; Coinfection; DNA, Viral; Drug Hypersensitivity Syndrome; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Guanine; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Virus Activation	2013
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group. International journal of molecular medicine, 2014, Volume: 33, Issue:6 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2014
Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Statistics, Nonparametric; Tacrolimus; Tandem Mass Spectrometry	2015
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Journal of hepatology, 2014, Volume: 61, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome	2014
Hepatitis C treatment & management. Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1 Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate	2014
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index	2014
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clinic proceedings, 2014, Volume: 89, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Treatment Outcome	2014
[Treatment of hepatitis C infection. A revolution should not hide another]. Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:4 Pt 1 Topics: Antiviral Agents; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Risk Reduction Behavior	2014
Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2014, Volume: 12, Issue:2 Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Viral Load	2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology, 2014, Volume: 147, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome	2014
Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. Journal of viral hepatitis, 2014, Volume: 21, Issue:5 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Humans; Interferons; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult	2014
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PloS one, 2014, Volume: 9, Issue:4 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Early Diagnosis; Female; Fibrosis; Genetic Variation; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin	2014
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS patient care and STDs, 2014, Volume: 28, Issue:5 Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2014
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. Journal of hepatology, 2014, Volume: 61, Issue:3 Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United States	2014
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11 Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. Journal of clinical gastroenterology, 2015, Volume: 49, Issue:4 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Young Adult	2015
Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2014
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC gastroenterology, 2014, May-05, Volume: 14 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Load	2014
[Treatment of hepatitis C: current status and perspectives]. La Revue du praticien, 2014, Volume: 64, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome	2014
KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. Human immunology, 2014, Volume: 75, Issue:8 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-B Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Receptors, KIR3DL1; Recombinant Proteins; Ribavirin; Viral Load	2014
Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. Journal of viral hepatitis, 2015, Volume: 22, Issue:2 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Young Adult	2015
Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antiviral therapy, 2015, Volume: 20, Issue:2 Topics: Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Biopsy; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load	2015
[Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:2 Topics: Adult; Aged; Antiviral Agents; Cellulitis; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Parotitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sepsis; Staphylococcal Infections; Treatment Outcome; Withholding Treatment	2015
[Management of side effects induced by antiviral therapy for chronic hepatitis infection]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hematinics; Hepatitis C, Chronic; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Treatment Outcome	2013
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Journal of medical virology, 2014, Volume: 86, Issue:11 Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Plasma; Proline; Ribavirin; Treatment Failure; Viral Load; Viral Nonstructural Proteins; Young Adult	2014
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:4 Topics: Antiviral Agents; Cost of Illness; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication	2014
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible? European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:9 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors	2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. Journal of viral hepatitis, 2015, Volume: 22, Issue:3 Topics: Aged; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load	2015
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Digestive diseases and sciences, 2014, Volume: 59, Issue:12 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Young Adult	2014
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. Applied health economics and health policy, 2014, Volume: 12, Issue:6 Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Severity of Illness Index	2014
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment]. Enfermedades infecciosas y microbiologia clinica, 2015, Volume: 33, Issue:5 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors	2015
The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir. PloS one, 2014, Volume: 9, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunity, Innate; Interferons; Interleukin-18; Lipopolysaccharide Receptors; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult	2014
Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir. Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:1 Topics: Aged; Antiviral Agents; Biopsy; Drug Eruptions; Female; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Risk Factors	2016
Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:2 Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Young Adult	2015
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Transplantation, 2015, Volume: 99, Issue:4 Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Recurrence; Retrospective Studies; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Virus Activation	2015
Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public health genomics, 2014, Volume: 17, Issue:5-6 Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome	2014
[A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:10 Topics: Acute Disease; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2014
[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Sep-16, Volume: 38, Issue:5 Topics: Anemia; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Oligopeptides; Polyethylene Glycols; Prevalence; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; Spain	2014
Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:12 Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult	2014
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:1 Topics: Acute Kidney Injury; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin	2015
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:5 Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2015
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS (London, England), 2015, Jan-02, Volume: 29, Issue:1 Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load	2015
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PloS one, 2014, Volume: 9, Issue:11 Topics: Antiviral Agents; Drug Monitoring; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Proline; Recombinant Proteins; Ribavirin; Signal Transduction; Treatment Outcome	2014
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. Journal of viral hepatitis, 2015, Volume: 22, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States; Veterans	2015
Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus. Oncology, 2014, Volume: 87 Suppl 1 Topics: Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Eruptions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Time Factors; Treatment Outcome; Viral Load	2014
Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C. Oncology, 2014, Volume: 87 Suppl 1 Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2014
Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:12 Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Outcome Assessment, Health Care; Patient Compliance; Pharmaceutical Services; Pharmacies; Polyethylene Glycols; Retrospective Studies; Ribavirin; United States	2014
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:3 Topics: Adult; Aged; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index	2015
Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Antiviral research, 2015, Volume: 113 Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Flavonoids; Hepacivirus; Hepatitis C; Interferon-alpha; Mice; Mice, Transgenic; Oligopeptides; Plant Extracts; Protease Inhibitors; Reactive Oxygen Species; Replicon; Ribavirin; RNA, Viral; Viral Proteins; Virus Replication	2015
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 29 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load	2014
[Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:8 Topics: Anti-Inflammatory Agents; Antiviral Agents; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Methylprednisolone; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin	2015
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. Antiviral therapy, 2015, Volume: 20, Issue:4 Topics: Antiviral Agents; Coinfection; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome	2015
Controlling hepatitis C with simeprevir. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:1 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides	2015
Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, Volume: 17, Issue:8 Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Models, Economic; Oligopeptides; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Severity of Illness Index	2014
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:2 Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans	2015
[Ways of improving adherence on telaprevir-based therapy in patients with chronic HCV infection]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2014, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Oligopeptides; Ribavirin	2014
Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012. Emerging infectious diseases, 2015, Volume: 21, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; New York; Oligopeptides; Pilot Projects; Prisoners; Protease Inhibitors; Ribavirin; Treatment Outcome	2015
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. Journal of clinical pharmacology, 2015, Volume: 55, Issue:5 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin	2015
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Proline; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2015
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:4 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin	2015
Severe cutaneous adverse reaction to telaprevir. Dermatology online journal, 2015, Jan-15, Volume: 21, Issue:1 Topics: Anti-Inflammatory Agents; Clobetasol; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Middle Aged; Oligopeptides; Ribavirin; Stevens-Johnson Syndrome	2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load	2015
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:3 Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Male; Middle Aged; Mutation; Oligopeptides; Protease Inhibitors; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome; Viral Load; Virus Replication	2015
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9 Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome	2015
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. Journal of clinical microbiology, 2015, Volume: 53, Issue:4 Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Diagnostic Techniques; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2015
Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:2 Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Pyrophosphatases; Ribavirin; Thrombocytopenia; Treatment Outcome	2015
[Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2015
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:8 Topics: Age Factors; Aged; Anemia; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyrophosphatases; Retrospective Studies; Ribavirin; Risk; Severity of Illness Index; Simeprevir; Viral Nonstructural Proteins	2015
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients. AIDS (London, England), 2015, May-15, Volume: 29, Issue:8 Topics: Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Spain; Tertiary Care Centers	2015
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. Journal of virology, 2015, Volume: 89, Issue:11 Topics: Adult; Aged; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Oligopeptides; Phylogeny; Protease Inhibitors; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins	2015
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive diseases and sciences, 2015, Volume: 60, Issue:4 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult	2015
[Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:9 Topics: Anemia, Aplastic; Anti-Bacterial Agents; Antiviral Agents; Blood Component Transfusion; Drug Therapy, Combination; Filgrastim; Folic Acid; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisone; Ribavirin; Viremia; Vitamin B 12	2015
Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience. Transplantation proceedings, 2015, Volume: 47, Issue:3 Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Outcome	2015
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PloS one, 2015, Volume: 10, Issue:4 Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2015
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. Journal of clinical microbiology, 2015, Volume: 53, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins	2015
Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients. Infectious diseases (London, England), 2015, Volume: 47, Issue:9 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin	2015
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World journal of gastroenterology, 2015, May-07, Volume: 21, Issue:17 Topics: Aged; Anemia, Aplastic; Antiviral Agents; Biopsy; Bone Marrow Examination; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Pancytopenia; Polyethylene Glycols; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome	2015
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. Journal of medical virology, 2015, Volume: 87, Issue:11 Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Protease Inhibitors; Ribavirin; Treatment Outcome; Young Adult	2015
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? Nephrology (Carlton, Vic.), 2015, Volume: 20, Issue:11 Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Kidney; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation	2015
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. Journal of viral hepatitis, 2015, Volume: 22, Issue:12 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Tertiary Care Centers; Treatment Outcome; Viral Load	2015
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance. Antiviral research, 2015, Volume: 120 Topics: Antiviral Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; Hepacivirus; Hepatocytes; Humans; Interferon-alpha; Oligopeptides; Purines; Pyridazines; Ribavirin; RNA, Viral	2015
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 68 Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult	2015
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. Journal of viral hepatitis, 2015, Volume: 22, Issue:12 Topics: Aged; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Japan; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Failure; Viral Nonstructural Proteins	2015
Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient. Acta gastroenterologica Latinoamericana, 2015, Volume: 45, Issue:1 Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome	2015
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:12 Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Propensity Score; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome	2015
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome	2016
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States	2015
THE ABSENCE OF THYROID DISEASE IN AN AUSTRALIAN HEPATITIS C COHORT TREATED WITH TRIPLE COMBINATION THERAPY: A PARADIGM SHIFT. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:9 Topics: Adult; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Thyroid Diseases	2015
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. Journal of medical virology, 2016, Volume: 88, Issue:1 Topics: Adult; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome	2016
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2015, Volume: 18, Issue:2 Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Regression Analysis; Retrospective Studies; Ribavirin; Tandem Mass Spectrometry	2015
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? Journal of clinical gastroenterology, 2016, Volume: 50, Issue:3 Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People	2016
The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 69 Topics: Aged; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sensitivity and Specificity; Viral Core Proteins	2015
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of viral hepatitis, 2015, Volume: 22, Issue:12 Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load	2015
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:10 Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides	2015
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. Journal of pharmacokinetics and pharmacodynamics, 2015, Volume: 42, Issue:6 Topics: Antiviral Agents; Biomarkers; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Models, Statistical; Nonlinear Dynamics; Oligopeptides; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2015
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. The Netherlands journal of medicine, 2015, Volume: 73, Issue:7 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response	2015
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:10 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain	2015
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. The International journal on drug policy, 2015, Volume: 26, Issue:10 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Opiate Substitution Treatment; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome	2015
Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy. Antiviral research, 2015, Volume: 123 Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood; Flow Cytometry; Hepatitis C, Chronic; Humans; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Liver; Longitudinal Studies; Middle Aged; Oligopeptides; Ribavirin; Young Adult	2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy. Antiviral therapy, 2016, Volume: 21, Issue:2 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin	2016
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. Medicine, 2015, Volume: 94, Issue:38 Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Carriers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Oligopeptides; Patient Acuity; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2015
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load	2016
Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:20 Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2015
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert opinion on drug safety, 2015, Volume: 14, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult	2015
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 73 Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Viral Load	2015
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. Oncology, 2015, Volume: 89 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load	2015
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. Reviews on recent clinical trials, 2016, Volume: 11, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome	2016
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. Journal of viral hepatitis, 2016, Volume: 23, Issue:5 Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Macrophages; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Staining and Labeling	2016
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus. Antiviral research, 2016, Volume: 126 Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication	2016
A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey. Acta clinica Belgica, 2015, Volume: 70, Issue:6 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2015
[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9 Topics: Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2015
[Telaprevir, peginterferon and ribavirin therapy for chronic hepatitis C]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9 Topics: Anemia; Drug Combinations; Hepatitis C, Chronic; Humans; Interferons; Kidney Function Tests; Oligopeptides; Ribavirin	2015
Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience. Acta gastro-enterologica Belgica, 2016, Volume: 79, Issue:1 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load; Young Adult	2016
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study. Medicine, 2016, Volume: 95, Issue:11 Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir	2016
Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy? The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2016, Volume: 27, Issue:2 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult	2016
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis. Gastroenterologia y hepatologia, 2017, Volume: 40, Issue:5 Topics: Anemia, Hemolytic; Antiviral Agents; Bacteremia; Blood Component Transfusion; Catheter-Related Infections; Drug Therapy, Combination; Glomerulonephritis; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Renal Dialysis; Ribavirin; Staphylococcal Infections; Thrombocytopenia	2017
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. International journal of medical sciences, 2016, Volume: 13, Issue:4 Topics: Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load	2016
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. AIDS (London, England), 2016, 08-24, Volume: 30, Issue:13 Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin	2016
[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study]. Annales de dermatologie et de venereologie, 2016, Volume: 143, Issue:5 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult	2016
Drug Pricing Evolution in Hepatitis C. PloS one, 2016, Volume: 11, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States	2016
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. The American journal of managed care, 2016, 06-01, Volume: 22, Issue:6 Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States	2016
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Jun-23, Volume: 49, Issue:7 Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult	2016
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report. Annals of transplantation, 2016, Jun-30, Volume: 21 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult	2016
[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy]. Revista da Escola de Enfermagem da U S P, 2015, Volume: 49, Issue:6 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin	2015
[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA]. Harefuah, 2016, Volume: 155, Issue:5 Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Israel; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome	2016
Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. PloS one, 2016, Volume: 11, Issue:8 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Principal Component Analysis; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2016
Eruptive seborrheic keratoses secondary to telaprevir-related dermatitis. Cutis, 2016, Volume: 98, Issue:2 Topics: Aged; Antiviral Agents; Drug Eruptions; Facial Dermatoses; Female; Hepatitis C, Chronic; Humans; Interferons; Keratosis, Seborrheic; Oligopeptides; Ribavirin	2016
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Oncology, 2016, Volume: 91, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult	2016
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. Journal of viral hepatitis, 2017, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Cohort Studies; Female; Healthcare Disparities; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Young Adult	2017
The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study. Biological & pharmaceutical bulletin, 2017, May-01, Volume: 40, Issue:5 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin	2017
Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study. Biological & pharmaceutical bulletin, 2017, May-01, Volume: 40, Issue:5 Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors	2017
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV. Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:10 Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation	2017
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC health services research, 2017, 04-19, Volume: 17, Issue:1 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ireland; Male; Middle Aged; Oligopeptides; Proline; Propensity Score; Prospective Studies; Registries; Ribavirin; Treatment Outcome; Uncertainty	2017
Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study. Biological & pharmaceutical bulletin, 2017, Sep-01, Volume: 40, Issue:9 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Odds Ratio; Oligopeptides; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin	2017
Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. Clinical immunology (Orlando, Fla.), 2017, Volume: 183 Topics: Aged; Antiviral Agents; B7-1 Antigen; B7-2 Antigen; Dendritic Cells; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome; Up-Regulation; Virus Replication	2017
Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment. AIDS research and therapy, 2017, Sep-20, Volume: 14, Issue:1 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Retrospective Studies; Ribavirin; Surveys and Questionnaires; Treatment Outcome	2017
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. Journal of immunology (Baltimore, Md. : 1950), 2018, 02-01, Volume: 200, Issue:3 Topics: Adaptive Immunity; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunologic Memory; Interferon-alpha; Longitudinal Studies; Lymphocyte Activation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; T-Box Domain Proteins; Treatment Outcome	2018
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in health regional issues, 2019, Volume: 20 Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Oligopeptides; Proline; Public Health Practice; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome	2019
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de saude publica, 2020, Volume: 36, Issue:2 Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin	2020
A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, Jan-29, Volume: 110, Issue:2 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Patient Selection; Polyethylene Glycols; Retrospective Studies; Ribavirin; South Africa; Treatment Outcome	2020
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:8 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Theoretical; Nonlinear Dynamics; Oligopeptides; Polyethylene Glycols; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2021
An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs. BMC complementary medicine and therapies, 2021, Oct-12, Volume: 21, Issue:1 Topics: Antiviral Agents; Artocarpus; Cell Line; Cyclosporine; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indonesia; Oligopeptides; Plant Extracts; Plant Leaves; Ribavirin	2021